Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (12): 1057-1062.doi: 10.35541/cjd.20210568

• Guidelines and Consensus • Previous Articles     Next Articles

Consensus on management of chronic urticaria using anti-immunoglobulin E therapy (omalizumab)

Centre for Urticaria Research, Chinese Society of Dermatology   

  1. Centre for Urticaria Research, Chinese Society of Dermatology
  • Received:2021-08-06 Revised:2021-09-26 Online:2021-12-15 Published:2021-12-01
  • Contact: Xu Jinhua

Abstract: 【Abstract】 Chronic urticaria is a common immune-related skin disorder with a persistent and recurrent course. Some patients poorly respond to antihistamines, whose quality of life may be severely impaired. Recently, various Chinese and international studies have shown that the anti-immunoglobulin E (IgE) therapy, which is primarily based on new biologic agents, is effective and well-tolerated in the treatment of chronic urticaria and other diseases. In order to standardize and promote the application and understanding of anti-IgE therapy by clinicians, the Centre for Urticaria Research of Chinese Society of Dermatology organized relevant experts to develop this consensus on the basis of international guidelines and relevant research reports in recent years. By taking omalizumab as an example, this consensus elaborates on specific mechanisms and treatment schemes of anti-IgE therapy in the treatment of chronic urticaria, as well as considerations during its use, with a view to providing a relevant theoretical basis and medication guidance for dermatologists.

Key words: Urticaria, Immunoglobulin E, Biological agents, Treatment outcome, Chronic urticaria, Anti-IgE therapy, Omalizumab